QR-Code

Relationship between canagliflozin use and sarcopenia: Real-world data from the United States

Aims: Real-world data were analyzed to evaluate the incidence and risk of sarcopenia for canagliflozin compared with other antihyperglycemic agents (AHAs) including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), empagliflozin, and dapagliflozin. Mate...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Zhong Yuan, Jill Hardin, James P. Gilbert, Jordy Mehawej, Saberi Rana Ali, Carolyn Jeffcoat, Sergio Fonseca
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2025-07-01
Schriftenreihe:Diabetes Epidemiology and Management
Schlagworte:
Real-world data
Type 2 diabetes mellitus
Canagliflozin
Sarcopenia
Propensity scores
Incidence
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2666970625000289
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge